Letter to the Editor

We read with interest the report by Subari et al1 in which they evaluated the difference in survival outcomes between therapy-related chronic myelomonocytic leukemia (CMML) and de novo CMML. They revealed that patients with therapy-related CMML had poorer survival than those with de novo CMML (median overall survival [OS], 11 vs. 20 months; P = .02).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Letter to the Editor Source Type: research